Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children

PHASE3CompletedINTERVENTIONAL

Enrollment

1,200

Participants

Timeline

Start Date

December 31, 2000

Primary Completion Date

September 30, 2003

Study Completion Date

December 31, 2003

Conditions

Influenza

Interventions

BIOLOGICAL

FluMist

Nasal Sprayer of one dosage of FluMist and other experimental

BIOLOGICAL

FluMist

Nasal sprayer of FluMist

OTHER

Placebo

Nasal Sprayer of Placebo